Cargando…

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights

SIMPLE SUMMARY: Trabectedin and lurbinectedin are two potent onco-therapeutic drugs for the treatment of advanced soft tissue sarcomas. Here we show that, in addition to cancer cells, these molecules exert important effects on macrophages and tissue-associated macrophages altering metabolic function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Povo-Retana, Adrián, Mojena, Marina, Stremtan, Adrian B., Fernández-García, Victoria B., Gómez-Sáez, Ana, Nuevo-Tapioles, Cristina, Molina-Guijarro, José M., Avendaño-Ortiz, José, Cuezva, José M., López-Collazo, Eduardo, Martínez-Leal, Juan F., Boscá, Lisardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590144/ https://www.ncbi.nlm.nih.gov/pubmed/33092171 http://dx.doi.org/10.3390/cancers12103060

Ejemplares similares

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
por: Povo-Retana, Adrián, et al.
Publicado: (2023)

Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells
por: Mojena, Marina, et al.
Publicado: (2018)

Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release
por: Jaén, Rafael I., et al.
Publicado: (2022)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Regulation of the H(+)-ATP synthase by IF1: a role in mitohormesis
por: Esparza-Moltó, Pau B., et al.
Publicado: (2017)

Protection against gamma-radiation injury by protein tyrosine phosphatase 1B
por: Mojena, Marina, et al.
Publicado: (2018)

Defining the metabolic signatures associated with human macrophage polarisation
por: Povo-Retana, Adrián, et al.
Publicado: (2023)

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
por: Lima, Michelle, et al.
Publicado: (2016)

Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia
por: Aquila, Giorgio, et al.
Publicado: (2020)

IF1 promotes oligomeric assemblies of sluggish ATP synthase and outlines the heterogeneity of the mitochondrial membrane potential
por: Romero-Carramiñana, Inés, et al.
Publicado: (2023)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma
por: Gadducci, Angiolo, et al.
Publicado: (2022)

Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance
por: Garcia-Martinez, Irma, et al.
Publicado: (2023)

Overexpression of the ATPase Inhibitory Factor 1 Favors a Non-metastatic Phenotype in Breast Cancer
por: García-Ledo, Lucía, et al.
Publicado: (2017)

Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth
por: Nuevo-Tapioles, Cristina, et al.
Publicado: (2020)

Dysfunctional oxidative phosphorylation shunts branched‐chain amino acid catabolism onto lipogenesis in skeletal muscle
por: Sánchez‐González, Cristina, et al.
Publicado: (2020)

Critical requirement of SOS1 RAS-GEF function for mitochondrial dynamics, metabolism, and redox homeostasis
por: García-Navas, Rósula, et al.
Publicado: (2021)

PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8(+) T lymphocytes
por: Ogando, Jesús, et al.
Publicado: (2019)

Overexpression of Mitochondrial IF1 Prevents Metastatic Disease of Colorectal Cancer by Enhancing Anoikis and Tumor Infiltration of NK Cells
por: González-Llorente, Lucía, et al.
Publicado: (2019)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells
por: Mascaraque, Marta, et al.
Publicado: (2020)

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report
por: Pedrinaci, Irene Zarcos, et al.
Publicado: (2012)

Lurbinectedin-induced thrombocytopenia: the role of body surface area
por: Papachristos, Apostolos, et al.
Publicado: (2022)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Effective therapeutic strategies in a preclinical mouse model of Charcot–Marie–Tooth disease
por: Nuevo-Tapioles, Cristina, et al.
Publicado: (2021)

The role of KRAS splice variants in cancer biology
por: Nuevo-Tapioles, Cristina, et al.
Publicado: (2022)

High-fat diet activates splenic NOD1 and enhances neutrophil recruitment and neutrophil extracellular traps release in the spleen of ApoE-deficient mice
por: Fernández-García, Victoria, et al.
Publicado: (2022)

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
por: Fudio, Salvador, et al.
Publicado: (2020)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
por: Gros, Louis, et al.
Publicado: (2021)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
por: Schultz, Christopher W, et al.
Publicado: (2023)

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells
por: Costanzo, Federico, et al.
Publicado: (2022)

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
por: Kristeleit, Rebecca, et al.
Publicado: (2021)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
por: Poveda, Andres, et al.
Publicado: (2021)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ilv4kee27mp67qbb00ouk3afdo